- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.11. | ArriVent BioPharma stock price target raised to $47 from $32 at Clear Street | 4 | Investing.com | ||
| 10.11. | ArriVent BioPharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11. | ArriVent BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.09. | ArriVent BioPharma appoints Brent Rice as chief commercial officer | 2 | Investing.com | ||
| ARRIVENT BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 22.09. | ArriVent BioPharma beruft Brent Rice zum Chief Commercial Officer | 1 | Investing.com Deutsch | ||
| 22.09. | ArriVent BioPharma, Inc.: ArriVent Appoints Brent S. Rice as Chief Commercial Officer | 218 | GlobeNewswire (Europe) | NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of... ► Artikel lesen | |
| 09.09. | ArriVent reports 16-month PFS for lung cancer drug firmonertinib | 1 | Investing.com | ||
| 09.09. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | ArriVent BioPharma GAAP EPS of -$0.90 misses by $0.20 | 1 | Seeking Alpha | ||
| 11.08. | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial Results | 829 | GlobeNewswire (Europe) | Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient... ► Artikel lesen | |
| 11.08. | ArriVent BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright | 1 | Investing.com | ||
| 21.07. | ArriVent BioPharma: Oppenheimer bestätigt Rating trotz verzögerter Studiendaten | 2 | Investing.com Deutsch | ||
| 21.07. | ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating | 1 | Investing.com | ||
| 21.07. | ArriVent expects topline data from lung cancer drug trial in early 2026 | 3 | Investing.com | ||
| 21.07. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | ArriVent BioPharma, Inc.: ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 | 389 | GlobeNewswire (Europe) | Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent... ► Artikel lesen | |
| 10.07. | ArriVent BioPharma: Goldman Sachs startet Coverage mit "Buy"-Rating | 2 | Investing.com Deutsch | ||
| 03.07. | ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval | 1 | Investing.com |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUVALENT | 105,88 | -1,97 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,56 | -0,13 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| QIAGEN | 40,380 | +2,38 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,170 | +8,45 % | Recursion (RXRX) Jumps 8% on Bargain-Hunting | ||
| BIONTECH | 83,05 | +0,06 % | Raus aus BioNTech? Rein in Evotec und Vidac Aktie? Was läuft da mit Johnson und Johnson? | Paukenschläge bei Biotechs: Partner Pfizer verkauft seine komplette Beteiligung am deutschen Biotech-Champion BioNTech. Sollten Anleger es genauso machen? Dagegen liefert Vidac Pharma mehr und mehr... ► Artikel lesen | |
| JANUX THERAPEUTICS | 28,800 | +0,73 % | Wolfe Research initiates Janux Therapeutics stock with Peerperform rating | ||
| PRAXIS PRECISION MEDICINES | 169,78 | +3,33 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Fireside Chat | ||
| COGENT BIOSCIENCES | 36,770 | +5,97 % | COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know | ||
| OLEMA PHARMACEUTICALS | 23,190 | +5,36 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| IMMUNOVANT | 22,580 | -0,92 % | Immunovant, Inc. - 8-K, Current Report | ||
| ARCUTIS BIOTHERAPEUTICS | 29,460 | +7,89 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| EVOTEC | 5,206 | +0,58 % | Evotec: Startet jetzt der Turnaround? | ||
| RAPPORT THERAPEUTICS | 27,250 | +1,49 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| IMMUNOME | 18,510 | +5,77 % | Varegacestat-Potenzial: Stephens erhöht Kursziel für Immunome auf 33 US-Dollar | ||
| MINERALYS THERAPEUTICS | 42,000 | +0,33 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen |
ARRIVENT BIOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,50 % bei einem Aktienkurs von 20,330 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARRIVENT BIOPHARMA INC finden Sie auf Wallstreet Online.